Contrasting GH Research (NASDAQ:GHRS) & Gyre Therapeutics (NASDAQ:GYRE)

GH Research (NASDAQ:GHRS) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Institutional and Insider Ownership

56.9% of GH Research shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 9.5% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

GH Research has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500.

Profitability

This table compares GH Research and Gyre Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-19.36%	-18.73%
Gyre Therapeutics	-5.44%	3.13%	2.67%

Analyst Ratings

This is a summary of recent ratings and price targets for GH Research and Gyre Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1	1	9	0	2.73
Gyre Therapeutics	2	0	2	0	2.00

GH Research presently has a consensus target price of $40.38, suggesting a potential upside of 41.72%. Gyre Therapeutics has a consensus target price of $17.00, suggesting a potential upside of 163.57%. Given Gyre Therapeutics’ higher possible upside, analysts plainly believe Gyre Therapeutics is more favorable than GH Research.

Valuation and Earnings

This table compares GH Research and Gyre Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26 million	($0.92)	-30.97
Gyre Therapeutics	$116.59 million	6.17	$5.03 million	($0.09)	-71.67

Gyre Therapeutics has higher revenue and earnings than GH Research. Gyre Therapeutics is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks.

Summary

Gyre Therapeutics beats GH Research on 8 of the 13 factors compared between the two stocks.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

About Gyre Therapeutics

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.